Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME_LUNG: Radiotherapy in Metastatic Lung Cancer
NCT05222087Phase 1Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jan 2022
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Feasibility of the study design at 18 months. Started Jan 2022; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05222087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222087.